argenx SE (NASDAQ:ARGX) Shares Bought by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lifted its position in argenx SE (NASDAQ:ARGX) by 10.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 75,037 shares of the company’s stock after buying an additional 7,146 shares during the period. Envestnet Asset Management Inc. owned approximately 0.12% of argenx worth $46,148,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. raised its position in argenx by 28.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,459 shares of the company’s stock worth $1,875,000 after acquiring an additional 768 shares in the last quarter. Captrust Financial Advisors bought a new stake in shares of argenx in the 3rd quarter worth approximately $243,000. HighTower Advisors LLC lifted its stake in argenx by 11.7% during the third quarter. HighTower Advisors LLC now owns 4,671 shares of the company’s stock valued at $2,558,000 after purchasing an additional 489 shares during the last quarter. Quantinno Capital Management LP lifted its stake in argenx by 18.9% during the third quarter. Quantinno Capital Management LP now owns 2,524 shares of the company’s stock valued at $1,368,000 after purchasing an additional 402 shares during the last quarter. Finally, Stifel Financial Corp boosted its holdings in argenx by 15.3% during the third quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock worth $4,788,000 after buying an additional 1,170 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ARGX. Wells Fargo & Company upped their price target on argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Citigroup reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. Oppenheimer lifted their price target on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Piper Sandler boosted their price objective on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a report on Tuesday, January 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $720.00 target price on shares of argenx in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $687.00.

argenx Price Performance

Shares of NASDAQ ARGX opened at $546.22 on Friday. argenx SE has a one year low of $352.77 and a one year high of $678.21. The business’s 50-day moving average price is $609.28 and its two-hundred day moving average price is $603.68. The company has a market capitalization of $33.19 billion, a P/E ratio of -620.70 and a beta of 0.60.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. The business had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. On average, equities analysts anticipate that argenx SE will post 3.13 EPS for the current year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.